超越BRCA:非BRCA同源重组修复通路基因变异携带者的降低风险手术模式
这项回顾性队列研究纳入三家医院318例非BRCA同源重组修复通路变异携带者,其中64例按NCCN标准或家族史符合降低风险输卵管卵巢切除术(RRSO)指征,仅31例(48%)接受了RRSO。未接受RRSO的合格患者中24例(73%)未转诊妇科肿瘤咨询。检测时年龄较大和转诊妇科肿瘤与RRSO采纳增加相关。
要点
- 符合RRSO指征的非BRCA同源重组修复通路变异携带者中,仅48%接受了RRSO。
- 未接受RRSO的合格患者中,73%未转诊妇科肿瘤咨询。
- 转诊妇科肿瘤与RRSO采纳增加相关(aOR 33.48)。
核心结论
- 按NCCN标准符合RRSO指征的非BRCA同源重组修复通路变异携带者中,一半未接受RRSO;存在通过改进教育增加转诊以促进RRSO的机会。
研究设计与样本
- 回顾性队列研究,纳入三家医院318例非BRCA同源重组修复通路变异携带者,其中卵巢癌风险增加变异(BRIP1、RAD51C、RAD51D)76例(24%),风险不确定变异(ATM、BARD1、NBN、PALB2)242例(76%)。
主要发现
- 318例中76例(24%)为风险增加变异(BRIP1 45例、RAD51C 20例、RAD51D 11例),242例(76%)为风险不确定变异(ATM 145例、PALB2 69例、NBN 23例、BARD1 5例)。
- 按NCCN标准或家族史符合RRSO指征的64例中,31例(48%)接受了RRSO。
- 符合指征但未接受RRSO的患者中,24例(73%)未转诊妇科肿瘤咨询。
- 检测时年龄较大(aOR 1.08,95%CI 1.03-1.13)和转诊妇科肿瘤(aOR 33.48,95%CI 8.10-138.39)与RRSO采纳增加相关,校正个人和家族乳腺癌及卵巢癌史。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The real-world management of patients with non-BRCA, homologous recombination repair pathway variants with increased or uncertain risks of ovarian cancer is unknown. The objective was to determine the adoption of risk-reducing salpingo-oophorectomy (RRSO) for carriers of variants with increased or uncertain risks of ovarian cancer beyond BRCA. METHODS: This was a retrospective cohort study of patients at three hospitals with non-BRCA, homologous recombination repair pathway variants with increased risk (BRIP1, RAD51C, RAD51D) and uncertain risk (ATM, BARD1, NBN, PALB2) of ovarian cancer. Outcomes of interest were adoption of RRSO and factors associated with adoption of RRSO. Wilcoxon rank-sum, chi-square, and logistic regression were performed with p < 0.05. RESULTS: Of 318 patients, 76 (24%) had pathogenic variants with increased risks of ovarian cancer (BRIP1, 45; RAD51C, 20; RAD51D, 11), and 242 (76%) had variants with uncertain risks of ovarian cancer (ATM, 145; PALB2, 69; NBN, 23; BARD1, 5). Of 64 patients eligible for RRSO by National Comprehensive Cancer Network (NCCN) criteria or family history, 31 (48%) underwent RRSO. Among eligible patients who did not undergo RRSO, 24 (73%) were not referred for gynecologic oncology consultation. Older age at testing (adjusted odds ratio [aOR] 1.08, 95% confidence interval [CI] 1.03-1.13) and referral to gynecologic oncology (aOR 33.48, CI 8.10-138.39) were associated with increased adoption of RRSO when adjusting for personal and family history of breast and ovarian cancer. CONCLUSION: Half of RRSO-eligible patients by NCCN criteria beyond BRCA did not undergo RRSO. Opportunities exist for improving education to increase referrals to facilitate RRSO for these patients.
引用
- Lee SS, Karpel HC, Oh C, et al. Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers. Gynecol Oncol. 2023. PMID: 36724586. doi:10.1016/j.ygyno.2022.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。